2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 975

Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function
Abstract Number: 1241

Further Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis of Morphea in Adults and Children
Abstract Number: 1161

Gadolinium-Enhanced Magnetic Resonance Imaging in Shoulders Contributes Accurate Diagnosis and Predicting Recurrence to Patients with Polymyalgia Rheumatica
Abstract Number: 1864

Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
Abstract Number: 264

Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort
Abstract Number: 2237

Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies
Abstract Number: 1873

Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap
Abstract Number: 577

Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients
Abstract Number: 629

Gender Differences in Comorbidities and Treatment Utilization Among Ankylosing Spondylitis Patients Initiating a Biologic in a Real-World Setting
Abstract Number: 2446

Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response
Abstract Number: 2484

Gender Influence on Treatment Effectiveness in Psoriatic Arthritis
Abstract Number: 1866

Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues
Abstract Number: 2023

Gene-Expression Analysis of Male and Female SLE Patients Reveals Candidate Pathogenic Pathways
Abstract Number: 1952

Genes Associated with Nucleotide Oligomerization Domain-Like Receptor Signaling Pathway Are Upregulated in Discoid Lupus Erythematosus
Abstract Number: 1004

Genetic Ablation of γδTCR Inhibits IL-23-induced Neutrophilia and Attenuates Epidermal Hyperplasia, Synovitis, Onycholysis and Enthesitis Associated with Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].